Peritoneal dialysis-associated peritonitis outcomes reported in trials and observational studies: A systematic review.

Nephrology/standards outcome assessment peritoneal dialysis peritoneal dialysis-associated peritonitis peritonitis research design systematic review

Journal

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis
ISSN: 1718-4304
Titre abrégé: Perit Dial Int
Pays: United States
ID NLM: 8904033

Informations de publication

Date de publication:
03 2020
Historique:
pubmed: 18 2 2020
medline: 15 5 2021
entrez: 18 2 2020
Statut: ppublish

Résumé

Peritoneal dialysis (PD)-associated peritonitis carries significant morbidity, mortality, and is a leading cause of PD technique failure. This study aimed to assess the scope and variability of PD-associated peritonitis reported in randomized trials and observational studies. Cochrane Controlled Register of Trials, MEDLINE, and Embase were searched from 2007 to June 2018 for randomized trials and observational studies in adult and pediatric patients on PD that reported PD-associated peritonitis as a primary outcome or as a part of composite primary outcome. We assessed the peritonitis definitions used, characteristics of peritonitis, and outcome reporting and analysis. Seventy-seven studies were included, three were randomized trials. Thirty-eight (49%) of the included studies were registry-based observational studies. Twenty-nine percent ( Large variability exists in the definitions, methods of reporting, and analysis of PD-associated peritonitis across trials and observational studies. Standardizing definitions for reporting of peritonitis and associated outcomes will better enable assessment of the comparative effect of interventions on peritonitis. This will facilitate continuous quality improvement measures through reliable benchmarking of this patient-important outcome across centers and countries.

Sections du résumé

BACKGROUND
Peritoneal dialysis (PD)-associated peritonitis carries significant morbidity, mortality, and is a leading cause of PD technique failure. This study aimed to assess the scope and variability of PD-associated peritonitis reported in randomized trials and observational studies.
METHODS
Cochrane Controlled Register of Trials, MEDLINE, and Embase were searched from 2007 to June 2018 for randomized trials and observational studies in adult and pediatric patients on PD that reported PD-associated peritonitis as a primary outcome or as a part of composite primary outcome. We assessed the peritonitis definitions used, characteristics of peritonitis, and outcome reporting and analysis.
RESULTS
Seventy-seven studies were included, three were randomized trials. Thirty-eight (49%) of the included studies were registry-based observational studies. Twenty-nine percent (
CONCLUSION
Large variability exists in the definitions, methods of reporting, and analysis of PD-associated peritonitis across trials and observational studies. Standardizing definitions for reporting of peritonitis and associated outcomes will better enable assessment of the comparative effect of interventions on peritonitis. This will facilitate continuous quality improvement measures through reliable benchmarking of this patient-important outcome across centers and countries.

Identifiants

pubmed: 32063197
doi: 10.1177/0896860819893810
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

132-140

Subventions

Organisme : AHRQ HHS
ID : R01 HS025756
Pays : United States

Commentaires et corrections

Type : CommentIn

Auteurs

Muthana Al Sahlawi (MA)

Division of Nephrology, St. Michael's Hospital and the Keenan Research Center in the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.
Department of Internal Medicine, College of Medicine, King Faisal University, Al-Hasa, Saudi Arabia.

Gregory Wilson (G)

Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.

Belinda Stallard (B)

Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.

Karine E Manera (KE)

Sydney School of Public Health, The University of Sydney, New South Wales, Australia.

Allison Tong (A)

Sydney School of Public Health, The University of Sydney, New South Wales, Australia.

Ronald L Pisoni (RL)

Arbor Research Collaborative for Health, Ann Arbor, MI, USA.

Douglas S Fuller (DS)

Arbor Research Collaborative for Health, Ann Arbor, MI, USA.

Yeoungjee Cho (Y)

Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.

David W Johnson (DW)

Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.
Centre for Kidney Disease Research, University of Queensland, Brisbane, Australia.
Translational Research Institute, Brisbane, Australia.

Beth Piraino (B)

Renal Electrolyte Division, University of Pittsburgh, PA, USA.

Martin J Schreiber (MJ)

Home Modalities, DaVita Kidney Care, Denver, CO, USA.

Neil C Boudville (NC)

Medical School, University of Western Australia, Perth, Australia.

Isaac Teitelbaum (I)

Division of Hypertension and Renal Diseases, University of Colorado Denver, Aurora, CO, USA.

Jeffrey Perl (J)

Division of Nephrology, St. Michael's Hospital and the Keenan Research Center in the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH